comparemela.com

Latest Breaking News On - Ron bentsur - Page 3 : comparemela.com

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Fort Lee, NJ, Aug. 17, 2023 Nuvectis Pharma, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious.

FDA Grants Orphan Drug Designation to NXP800 for Cholangiocarcinoma

FDA Grants Orphan Drug Designation to NXP800 for Cholangiocarcinoma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Insiders Buying Joint Corp And 2 Other Stocks - Joint (NASDAQ:JYNT), Byrna Technologies (NASDAQ:BYRN)

Insider Buying: Nuvectis Pharma, Inc (NASDAQ:NVCT) CEO Buys $12,375 00 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT – Free Report) CEO Ron Bentsur acquired 750 shares of the stock in a transaction dated Monday, June 26th. The stock was acquired at an average cost of $16.50 per share, with a total value of $12,375.00. Following the purchase, the chief executive officer now owns 3,230,779 shares of the company’s […]

Ron Bentsur Acquires 750 Shares of Nuvectis Pharma, Inc (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT – Get Rating) CEO Ron Bentsur purchased 750 shares of the firm’s stock in a transaction that occurred on Monday, June 26th. The stock was bought at an average cost of $16.50 per share, for a total transaction of $12,375.00. Following the completion of the purchase, the chief executive officer now […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.